Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 28, Issue 4, 1999, Pages 418-422

  Weber, Peter ^a,b   Husemann, Stephanie ^a   Vielhaber, Heinrich ^a   Zimmer, Klaus Peter ^a   Nowak Göttl, Ulrike ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Coagulation; Crohn's disease; Fibrinolysis; Ulcerative colitis

Indexed keywords

LIPOPROTEIN A; PROTEIN C; PROTEIN S; THROMBOMODULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

EID: 0033498635     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199904000-00013     Document Type: Article

References (31)

1. Lloyd-Still JD, Tomasi L. Neurovascular and thromboembolic complications of inflammatory bowel disease in childhood. J Pedialr Gastroenterol Nutr 1989;9:461-6.
2. Mezoff AG, Cohen MB, Maisel SK, Farrell MK. Crohn disease in an infant with central nervous system thrombosis and protein-losing enteropathy. J Pediatr 1990;117:436-9.
3. Gormally SM, Bourke W, Kierse B, Monaghan H, McMenamin J, Drumm B. Isolated cerebral thrombo-embolism and Crohn disease. Eur J Pediatr 1995;154:815-8.
4. Wakefield AJ, Sawyer AM, Dhillon AP, et al. Lancet 1989;339ii: 1057-62.
5. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883-9.
6. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61: 140-5.
7. Novacek G, Vogelsang H, Genser D, et al. Changes in blood rheology caused by Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:1089-93.
8. Conlan MG, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989;34:1089-93.
9. Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995;7:1183-8.
10. Smith CJ, Haire WD, Kaufman SS, Mack DR. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996;91:1221-5.
11. Nowak-Göttl U, Wolff JEA. Kuhn N, et al. Enhanced thrombin generation. P-von Willebrand factor, P-Fibrin, D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis 1994;8:63-5.
12. Nowak-Göttl U, Funk M, Mosch G, et al. Univariate tolerance regions for fibrinogen, antithrombin III, protein C, protein S, plasminogen and alpha-2-antiplasmin in children using the new coagulation laboratory (ACL) method. Klin Padiatr 1994;206:436-8.
13. Nowak-Göttl U, Koch HG, Aschka I, et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996;92:992-8.
14. Kohlhase B, Vielhaber H, Kehl HG, Kececioglu D, Koch HG, Nowak-Göttl U. Thromboembolism and resistance to activated protein C in children with underlying cardiac disease. J Pediatr 1996;129:677-9.
15. Simoni P, Scarano L, Gavasso S, et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996;92:435-41.
16. Zöller B, Holm J, Svensson P, Dahlbacker B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg 506 to Gln mutation in the factor V gene. Thromb Haemost 1996;75:270-4.
17. Nowak-Göttl U, Vielhaber H. Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene. Eur J Haematol 1997;58:51-5.
18. Nowak-Göttl U, Binder M, Dübbers A, et al. Arg 506 to Gln mutation in the factor V gene causes poor fibrinolytic response after venous occlusion. Thromb Haemost 1997;78:1115-18.
19. Nowak-Göttl U, Vielhaber H, Schneppenheim R, Koch HG. Co-agulation and fibrinolysis in children with APC resistance: A population study. Fibrinolysis 1996;10:25-7.
20. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
21. Rachmilewitz D, on behalf of an international study group. Coated mesalazine (5-aminosalicyclic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ 1989;298:82-6.
22. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995;9:946-55.
23. Inoh M, Tokuda M, Kiuchi H, Kurata N, Takahara J. Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis. Arthritis Rheum 1996;39:287-91.
24. Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996;75:892-8.
25. Brignola C, Lanfranchi GA, Campieri M et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986;8:245-8.
26. Talstad I, Rotwelt K, Gione E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973;8:135-8.
27. Wiman B. Plasminogen activator inhibitor-1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost 1995;74:71-6.
28. Margaglione M, Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor 1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994;14:1741-5.
29. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989;9:87-98.
30. Patrassi GM, Sartori MT, Viero ML, et al. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinol 1992;3:789.
31. Nowak-Göttl U, Ahlke E, Schulze-Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haemotol 1996;95:123-6.